miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
出版年份 2018 全文链接
标题
miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
作者
关键词
-
出版物
CANCER GENE THERAPY
Volume 25, Issue 3-4, Pages 68-76
出版商
Springer Nature
发表日期
2018-01-05
DOI
10.1038/s41417-017-0005-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Perspectives of HER2-targeting in gastric and esophageal cancer
- (2017) James N Gerson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The EMT spectrum and therapeutic opportunities
- (2017) Dominic C. Voon et al. Molecular Oncology
- MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells
- (2017) Tao Jiang et al. ONCOLOGY REPORTS
- Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines
- (2017) Xin Wang et al. Oncotarget
- Targeted therapies for gastric cancer: failures and hopes from clinical trials
- (2017) Maria Apicella et al. Oncotarget
- Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease
- (2017) Manish A. Shah et al. Journal of the National Comprehensive Cancer Network
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
- (2016) G. Piro et al. CLINICAL CANCER RESEARCH
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
- (2016) Chiara Arienti et al. Oncotarget
- Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
- (2015) Sharon T. Wilks BREAST
- Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
- (2015) Adela Madrid-Paredes et al. BREAST CANCER RESEARCH AND TREATMENT
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
- (2015) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
- (2015) Rocco Cappellesso et al. HUMAN PATHOLOGY
- Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma
- (2015) DH Jensen et al. JOURNAL OF PATHOLOGY
- A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
- (2014) Carlos Gomez-Martín et al. CANCER LETTERS
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53
- (2012) Xinliang Zhou et al. LIFE SCIENCES
- Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population
- (2012) Hasan Korkaya et al. MOLECULAR CELL
- HER2 Testing in Gastric Cancer
- (2010) Luca Albarello et al. ADVANCES IN ANATOMIC PATHOLOGY
- The role of the miR-200 family in epithelial-mesenchymal transition
- (2010) Perry S. Mongroo et al. CANCER BIOLOGY & THERAPY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Targeted HER2 Treatment in Advanced Gastric Cancer
- (2010) Jan Trøst Jørgensen ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More